Previous 10 | Next 10 |
PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions...
Sonoma Pharmaceuticals (NASDAQ: SNOA ): Q3 GAAP EPS of -$0.72. More news on: Sonoma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PETALUMA, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quarterly Net Loss Reduced by 53% Compared to Prior Year YTD Net Loss Reduced by 82% Compared to Prior Year Total YTD Revenues of $14.4 Million Lower by 2% Compared to Prior Year Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), ...
PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today an...
PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of its common stock at a public offering price of $3.50 per share, with anticipated ...
Movado Group (NYSE: MOV ) -20% on Q3 earnings . More news on: Movado Group, Inc., ASLAN Pharmaceuticals Limited, Sonoma Pharmaceuticals, Inc., Stocks on the move, Read more ...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) launches a public offering of common shares. Price, volume and terms have yet to be announced. More news on: Sonoma Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock. Dawson James Securities, Inc. is acting as the lead placement agent and sole book ru...
Sonoma Pharmaceuticals (NASDAQ: SNOA ): Q2 net loss of $1.2M Revenue of $4.96M (+0.4% Y/Y) beats by $0.26M . Press Release More news on: Sonoma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies ...
News, Short Squeeze, Breakout and More Instantly...
Sonoma Pharmaceuticals Inc. Company Name:
SNOA Stock Symbol:
NASDAQ Market:
Sonoma Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and ...